Form 4: Gyre Therapeutics President Sells Shares Under 10b5-1 Trading Plan

Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock on May 14 and 15, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Songjiang Ma, President of Gyre Therapeutics, sold shares of the company's common stock.
• The sales occurred on May 14 and 15, 2025.
• The transactions were executed under a Rule 10b5-1 trading plan adopted on September 13, 2024.
• On May 14, 20 shares were sold at a weighted average price of $11.30.
• On May 15, 2,000 shares were sold at prices ranging from $10.435 to $10.93, with a weighted average price of $10.68.
• Following these transactions, Ma indirectly owns 2,818,824 shares through his spouse.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting stock sales by an officer. It doesn't inherently convey positive or negative sentiment, as it's simply a factual disclosure.

Industry Context

Sales by company presidents are common and are often pre-planned to avoid accusations of insider trading. The use of a 10b5-1 plan suggests the sales were scheduled in advance.

Stakeholder Impact

• The stock sale could have a minor impact on shareholder sentiment, depending on how the market interprets the transaction.

Key Dates

Keywords

Form 4, insider trading, stock sale, Rule 10b5-1, Gyre Therapeutics, Songjiang Ma, GYRE